Bank of America (BAC), inclusive of yesterday's poor trading, has still provided investors a 37.9% return in the last 12 months, and has recently upped its dividend after passing its Federal Stress Test in the last month.
Throughout 2014, the bank has continued to make progress in this regard. It's been settling litigation left and right, and CEO Brian Moynihan appears to continue steering the ship in the right direction. USA Today reported on recent litigation leading up to the bank's earnings:
Bank of America in March agreed to pay $9.3 billion to settle claims it marketed risky mortgages to Fannie Mae and Freddie Mac. At the same time, the bank reached a $15 million settlement with the New York State Attorney General's office over its 2009 purchase of Merrill Lynch.
And on April 9, the bank also agreed to pay $772 million in refunds and fines to settle allegations by the Consumer Financial Protection Bureau and the Office of Comptroller of the Currency that it had bilked millions of customers with deceptive credit card practices. The agreement was "in line with what we expected," bank spokesman Tony Allen said last week.
Top 5 Casino Stocks To Watch For 2015: Coty Inc (COTY)
Coty Inc., incorporated on January 20, 1995, is engaged in manufacturing, marketing and distribution of women�� and men�� fragrances, color cosmetics and skin and body care related products globally. The Company operates in three segments: Fragrances, Color Cosmetics and Skin & Body Care. The Company�� power brands consist of adidas, Calvin Klein, Chloe, Davidoff, Marc Jacobs, OPI, philosophy, Playboy, Rimmel and Sally Hansen. The Company sells products in each of its segments through retailers, including hypermarkets, supermarkets, independent and chain drug stores and pharmacies, upscale perfumeries, upscale and mid-tier department stores, nail salons, specialty retailers, duty-free shops and traditional food, drug and mass retailers.
The Company�� Fragrance products include a range of men�� and women�� products, with brands associated with fashion designers, celebrities and lifestyle brands. Color Cosmetics products include nail, lip, eye and other facial color products. Skin & Body Care products include shower gels, deodorants, skin care and sun treatment products.
Advisors' Opinion:- [By Maria Armental var popups = dojo.query(".socialByline .popC"); popups.forEach]
Coty Inc.(COTY) swung to a loss for the first three months of the year after the beauty-products maker posted a large write-down in its skin and body care segment. However, results beat expectations. Shares rose 1% to $15.60 premarket.
Hot Gas Utility Stocks To Buy For 2014: PetMed Express Inc.(PETS)
PetMed Express, Inc., doing business as 1-800-PetMeds, operates a pet pharmacy in the United States. It markets non-prescription and prescription pet medications; and other health products for dogs and cats, as well as direct to consumers. The company?s non-prescription medications include flea and tick control products, bone and joint care products, vitamins and nutritional supplements, and hygiene products. Its prescription medications comprise heartworm preventatives; arthritis, thyroid, diabetes, and pain medications; antibiotics and other specialty medications; and generic substitutes. In addition, the company, through its Web site, 1800petmeds.com, sells beds, crates, stairs, strollers, and other pet supplies. PetMed Express offers its products under the Frontline Plus, K9 Advantix, Advantage, Heartgard Plus, Sentinel, Interceptor, Program, Revolution, Deramaxx, and Rimadyl brands. The company markets its products through national television, online, and direct mail /print advertising campaigns, as well as through telephone, catalogs, brochures, and postcards. It primarily serves retail customers. PetMed Express was founded in 1996 and is headquartered in Pompano Beach, Florida.
Advisors' Opinion:- [By Bryan Murphy]
The two-year soft patch for Petmed Express Inc. (NASDAQ:PETS) may well be over; we'll know for sure on Monday. The two-year dry spell for faithful PETS shareholders may also be over. In fact, the chart says the stock's already in a new uptrend, and the company has a chance to cement that budding move into place when earnings are unveiled early next week.
- [By Seth Jayson]
PetMed Express (Nasdaq: PETS ) is expected to report Q1 earnings around July 15. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict PetMed Express's revenues will grow 1.3% and EPS will increase 10.0%. - [By Sean Williams]
The most logical choice to invest in a burgeoning and ongoing domestication of our pets is by looking into pet superstores like PetSmart (NASDAQ: PETM ) . While online companies like PetMed Express (NASDAQ: PETS ) offer the convenience of ordering medications from the comfort of your home, pets -- like humans -- need personalized care that you usually just can't get from the click of a mouse. This means that PetSmart is bound to stay busy with physical store visits from consumers who want only the best for Fido or their feline. And the proof is certainly in the pudding --PetSmart hasn't delivered an annual revenue decline once over the past decade with total sales up 125% since 2004.
- [By Peter Graham]
The Q1 2014 earnings report for pet supply retailer PetSmart, Inc (NASDAQ: PETM), a brick and mortar peer of online Petmed Express Inc (NASDAQ: PETS), is due out before the market opens on Wednesday. Aside from the PetSmart earnings report, it should be said that Petmed Express Inc reported�Q4 2013 earnings on May 5th (sales slipped 4.9% to $48.6 million while net income came in at $4.5 million�verses $4.6 million���results that were blamed on severe winter weather). However,�PetSmart did get some downgrades recently with analyst saying there is increased competition in the pets space.
Hot Gas Utility Stocks To Buy For 2014: Excel Trust Inc (EXL)
Excel Trust, Inc., incorporated on December 15, 2009, is a vertically integrated, self-administered, self-managed real estate investment trust (REIT). The Company�� principal objective is to acquire, finance, develop, lease, own and manage value-oriented community and power centers, grocery anchored neighborhood centers and freestanding retail properties. The Company conducts all of its business through Excel Trust, L.P., a limited partnership, or its operating partnership. The Company operates through three reportable business segments: retail properties, multi-family properties and office properties. The multi-family segment consists of apartment units at one retail property, West Broad Village, which is located in Richmond, Virginia. The office segment consists of two properties, Excel Centre, a portion of which is utilized as its headquarters, and the Promenade Corporate Center. The Company is the sole general partner of its operating partnership. Excel Trust leases its properties to national and regional supermarket chains, big-box retailers and select national retailers that offer necessity and value oriented items and generate regular consumer traffic. In October 2012, the Company acquired six shopping centers. On January 24, 2013, the Company completed the acquisition of Tracy Pavilion, a retail shopping center with approximately 162,000 square feet of gross leasable area located in Tracy, California. In September 2013, the Company announced the sale of Grant Creek Town Center.
As of December 31, 2012, the Company owned a portfolio consisting of 30 retail properties totaling approximately 5.1 million square feet of gross leasable area, which were approximately 93.4% leased. The Company owns two commercial office properties, Excel Center, a portion of which is utilized as its corporate headquarters, and the Promenade Corporate Center. As of December 31, 2012, the Company had ownership interests in two unconsolidated retail properties totaling 225,113 square feet of gross leasable! area, which were approximately 65.5% leased.
Advisors' Opinion:- [By Marc Bastow]
Commercial and retail property owner-operator and real estate investment trust Excel Trust (EXL) raised its quarterly dividend 3% to 17.5 cents per share, payable on Jan. 15 to shareholders of record as of Dec. 31.
EXL Dividend Yield: 6.04%
Hot Gas Utility Stocks To Buy For 2014: Idenix Pharmaceuticals Inc.(IDIX)
Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral diseases in the United States and Europe. Its primary research and development focus is on the treatment of patients with hepatitis C virus (HCV). The company?s HCV discovery program focuses on various classes of drugs, including nucleoside/nucleotide polymerase inhibitors, protease inhibitors, non-nucleoside polymerase inhibitors, and NS5A inhibitors. It develops products and drug candidates for the treatment of patients with hepatitis B virus (HBV), human immunodeficiency virus (HIV) type-1, and acquired immune deficiency syndrome (AIDS). The company principally has a collaboration agreement with Novartis Pharma AG for the development and commercialization of telbivudine, a drug for the treatment of HBV under the Tyzeka/Sebivo names. Idenix Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Advisors' Opinion:- [By Dan Carroll]
Idenix Pharmaceuticals (NASDAQ: IDIX ) also ranked among biotech's top risers this week by gaining 6.5%. This stock's suffered through a rough year, as shares have lost more than 25% year to date. That's entirely due to the FDA's request for more data on its hepatitis C therapy IDX20963, an event that by itself smashed the stock by more than 30% in late June -- and shares have yet to recover. Idenix dropped two other hepatitis C compounds earlier in the year, although the company's still pursing mid-stage drug IDX719 in the all-oral hepatitis C pursuit.
- [By Bryan Murphy]
Think patent wars are only being fought - and won - by consumer technologies like Vringo, Inc. (NASDAQ:VRNG) and Apple Inc. (NASDAQ:AAPL)? Think again. While the Vringo patent war with Google Inc. (NASDAQ:GOOG) and the Apple infringement case against Samsung may have been the world's highest-profile patent litigation conflicts (and most covered by the media), patent infringement claims and subsequent court cases have become just as common within the biotech world. Just ask Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) and Gilead Sciences, Inc. (NASDAQ:GILD)... two biotech names that are currently duking it out over patents that look nearly identical. Indeed, a coin toss may be just as fair of a way to decide who's right and who's wrong between Idenix and Gilead.
Hot Gas Utility Stocks To Buy For 2014: Alexza Pharmaceuticals Inc.(ALXA)
Alexza Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. Its product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. The company?s lead product candidate includes ADASUVE (Staccato loxapine) for the acute treatment of agitation in adults with schizophrenia or bipolar disorder. Its other product candidates under development comprise AZ-007 (Staccato zaleplon), which has completed Phase I clinical trials for the treatment of insomnia; and Staccato nicotine that is in pre-Phase 1 clinical trials to help smokers quit by addressing both the chemical and behavioral components of nicotine addiction by delivering nicotine replacement through inhalation. The company was f ormerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. Alexza Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Mountain View, California.
Advisors' Opinion:- [By anandjha89]
Company like Alexza Pharmaceuticals (ALXA). It has developed an aerosol delivery system for already-approved drugs, called the Staccato system. The company�� first product, ADASUVE was approved in January 2013. It combines a 1974-vintage anti-psychotic drug, loxapine, with the company�� new delivery device.
- [By Roberto Pedone]
Another under-$10 stock that's starting to move within range of triggering a big breakout trade is Alexza Pharmaceuticals (ALXA), which is focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. This stock hasn't done much so far in 2013, with shares up by just 5.6%.
If you take a look at the chart for Alexza Pharmaceuticals, you'll notice that this stock has been uptrending strong for the last month, with shares moving higher from its low of $4.23 to its recent high of $5.52 a share. Following that uptrend, shares of ALXA have now started to trend sideways and consolidate between $4.95 on the downside and $5.52 on the upside. Shares of ALXA are now starting to spike within range of triggering a big breakout trade above the upper-end of its recent sideways trading chart pattern.
Market players should now look for long-biased trades in ALXA if it manages to break out above some near-term overhead resistance levels at $5.40 to $5.52 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 256,570 shares. If that breakout triggers soon, then ALXA will set up to re-test or possibly take out its 52-week high at $6.65 a share, or its next major overhead resistance level at $7.60 a share.
Traders can look to buy ALXA off weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average at $4.77 a share, or near its 200-day moving average at $4.63 a share. One can also buy ALXA off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By Roberto Pedone]
Alexza Pharmaceuticals (ALXA) is a pharmaceutical company focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. This stock closed up 1.9% to $4.63 in Tuesday's trading session.
Tuesday's Range: $4.51-$4.73
52-Week Range: $2.91-$6.65
Tuesday's Volume: 509,000
Three-Month Average Volume: 421,914From a technical perspective, ALXA trended modestly higher here right off its 50-day moving average at $4.48 with above-average volume. This move is quickly moving shares of ALXA within range of triggering a major breakout trade. That trade will hit if ALXA manages to take out some near-term overhead resistance levels at $4.80 to $4.86 and then once it clears more resistance at $5.20 with high volume.
Traders should now look for long-biased trades in ALXA as long as it's trending above its 50-day at $4.48 or above more support at $4.20 and then once it sustains a move or close above those breakout levels with volume that hits near or above 421,914 shares. If that breakout triggers soon, then ALXA will set up to re-test or possibly take out its 52-week high at $6.65.
Hot Gas Utility Stocks To Buy For 2014: Ishares Trust Dow Jones Select Dividend (DVY)
iShares Dow Jones Select Dividend Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Dividend Index (the Index). The Index measures the performance of a selected group of equity securities issued by companies that have provided relatively high dividend yields on a consistent basis over time. The Index stocks are screened by dividend-per-share growth rate, dividend payout percentage and average daily dollar trading volume, and are selected based on dividend yield.
The Index consists of 100 of the highest dividend-yielding securities (excluding real estate investment trusts) in the Dow Jones U.S. Total Market Index, an index representative of the total market for United States equity securities. To be included in the Index, the securities must have had a flat to positive dividend-per-share growth rate for each of the last five years; must have an average five-year dividend payout ratio of 60% or less, and must have a minimum three-month average trading volume of 200,000 shares a day. The Index is reconstituted annually. The Fund uses a representative sampling strategy in seeking to track the Index. The Fund�� investment advisor is Barclays Global Fund Advisors.
Advisors' Opinion:- [By Jim Pyke]
If you recall my previous article that looked at iShares Dow Jones Select Dividend Index (DVY) and SPDR S&P Dividend ETF (SDY), there is an interesting comparison. While both SDY and DVY were underweight in Energy-Oils by substantial margin, both VIG and VYM are overweight in this sector. VIG has a 13.2% of its assets and VYM is at 13.0% relative to the market at 10.5%.
No comments:
Post a Comment